Pfizer CEO says Omicron variant targeted vaccine is most likely outcome

1 minute read

Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021. John Thys /Pool via REUTERS

Register now for FREE unlimited access to Reuters.com

NEW YORK, Jan 10 (Reuters) - Pfizer Inc (PFE.N) Chief Executive Albert Bourla said on Monday that moving toward a redesigned COVID-19 vaccine that is specifically targeted to combat the Omicron variant of the coronavirus is the "most likely scenario."

Speaking at the J.P. Morgan Healthcare Conference, Bourla said Pfizer and partner BioNTech SE are working on both an Omicron-targeted vaccine variant as well as a shot that would include both the previous vaccine as well as vaccine targeted at the Omicron variant.

Bourla said the company could be ready to file for approval for a redesigned vaccine and start producing it as soon as March.

Register now for FREE unlimited access to Reuters.com
Reporting by Michael Erman, Editing by Franklin Paul

Our Standards: The Thomson Reuters Trust Principles.